We evaluated the expression of MCM3 and AURKA by immunohistochemistry in metastatic lesions from ER+ advanced breast cancer patients treated with combined CDK4/6i and endocrine therapy (n = 86). This evidence concerns the gene ESR1 and breast carcinoma.